 Home > Active Ingredient News > Study of Nervous System > Alzheimer & Dementia: Targeting Aβ to treat Alzheimer's disease?

Alzheimer & Dementia: Targeting Aβ to treat Alzheimer's disease?

 Last Update: 2021-11-02
 Source: Internet
 Author: User

Tags

trophic effect

menkes disease symptoms

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Although the deposition of amyloid fibrin β (Aβ) in the brain is determined to be one of the earliest pathological changes, it has occurred at least ten years before the clinical diagnosis of Alzheimer's disease (AD) , but so far, it has been targeted at Aβ The treatment of is basically ineffective in slowing down cognitive decline.

Diagnosis of Aβ treatment is basically ineffective in slowing down cognitive decline.

It is also possible that not all cognitive declines, even if diagnosed as AD, are not due to neurodegeneration caused by Aβ and tau

The study used partial least squares structural equation pathway model to evaluate imaging biomarkers (global Aβ-PET uptake, regional tau-PET uptake, and MRI-based regional atrophy) among 248 Aβ-positive elderly with cognitive impairment and dementia.

The results showed that Aβ accounted for 16% of the cross-sectional cognitive impairment variation, tau accounted for 46%-47%, brain atrophy accounted for 25%-29%, but 53%-58% of the total cognitive impairment variation was caused by AD risk factors Intermediary and direct effects explained

Aβ accounts for 16% of the cross-sectional cognitive impairment variation, tau accounts for 46%-47%, and brain atrophy accounts for 25%-29%.

The influence of AD risk factors on the overall AD continuity of mPACC and ADAS-Cog measured by baseline cognitive outcome

To a large extent, the important pathways identified in the cognitive decline model are similar to the pathways in the baseline cognitive impairment model, but men have a significant direct impact on the latent variable (LV) of tau, but they have no effect on any index of cognitive decline.

Larger WML has a significant direct effect on ΔADAS-Cog, but no effect on ΔmPACC

In summary, the study suggests that treatments that remove the effects of Aβ and tau on neurodegeneration and downstream effects may not be very effective in slowing down cognitive decline or reversing cognitive impairment in Alzheimer's disease

references:

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum.

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.